Metabolic emergencies

Critical Reviews in Oncology/Hematology

Volumn 58, Issue 1, 2006, Pages 79-89

  Spinazzé, Silvia ^a   Schrijvers, Dirk ^b  

^a START Project   (Italy)

^b ZNA Middelheim   (Belgium)

Author keywords

Hypercalcaemia; Metabolic emergencies; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; HYDROCORTISONE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADRENAL INSUFFICIENCY; ARTICLE; BONE PAIN; BRAIN DISEASE; BREAST CARCINOMA; CANCER PATIENT; HUMAN; HYPERAMMONEMIA; HYPERCALCEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPONATREMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; METABOLIC DISORDER; NAUSEA; RISK FACTOR; TUMOR CELL DESTRUCTION; UREMIA; VOMITING;

EID: 33644954477     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.04.004     Document Type: Review

References (41)

1. J.F. Seymour, and R.F. Gagel Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas Blood 82 1993 1383 1394
2. K.A. Nelson, D. Walsh, and O. Abdullah Common complications of advanced cancer Semin Oncol 27 2000 34 44
3. C.D. Flombaum Metabolic emergencies in the cancer patient Semin Oncol 27 2000 322 334
4. J.J. Body Current and future directions in medical therapy: hypercalcemia Cancer 88 2000 3054 3058
5. G.N. Hortobagyi, R.L. Theriault, A. Lipton Protocol 19 Aredia Breast Cancer Study Group Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16 1998 2038 2044
6. J.R. Berenson, A. Lichtenstein, L. Porter Myeloma Aredia Study Group Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events J Clin Oncol 16 1998 593 602
7. J.A. Kanis, and E.V. McCloskey Clodronate Cancer 80 1997 1691 1695
8. L.S. Rosen, D. Gordon, and M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 2001 377 387
9. J.J. Body, R. Bartl, P. Burckhardt International Bone and Cancer Study Group Current use of bisphosphonates in oncology J Clin Oncol 16 1998 3890 3899
10. S.R. Nussbaum, J. Younger, and C.J. Vandepol Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages Am J Med 95 1993 297 304
11. O.P. Purohit, C.R. Radstone, C. Anthony, J.A. Kanis, and R.E. Coleman A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy Br J Cancer 72 1995 1289 1293
12. R. Gucalp, P. Ritch, and P.H. Wiernik Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia J Clin Oncol 10 1992 134 142
13. J. Vinholes, C.Y. Guo, O.P. Purohit, R. Eastell, and R.E. Coleman Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy J Clin Oncol 15 1997 131 138
14. N.P. O'Rourke, E.V. McCloskey, S. Vasikaran, K. Eyres, D. Fern, and J.A. Kanis Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate Br J Cancer 67 1993 560 563
15. P. Major, A. Lortholary, and J. Hon Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 2001 558 567
16. UKMF. The UK Myeloma Forum. Diagnosis and management of multiple myeloma. Br J Haematol 2001;115:522-40.
17. M. Pecherstorfer, Z. Herrmann, and J.J. Body Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy J Clin Oncol 14 1996 268 276
18. S.H. Ralston, D. Thiebaud, and Z. Herrmann Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia Br J Cancer 75 1997 295 300
19. N. Zojer, A.V. Keck, and M. Pecherstorfer Comparative tolerability of drug therapies for hypercalcaemia of malignancy Drug Saf 21 1999 389 406
20. Warrell RPJ, R. Israel, M. Frisone, T. Snyder, J.J. Gaynor, and R.S. Bockman Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized, double-blind comparison to calcitonin Ann Intern Med 108 1988 669 674
21. Warrell RPJ, W.K. Murphy, P. Schulman, P.J. O'Dwyer, and G. Heller A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia J Clin Oncol 9 1991 1467 1475
22. R.P.J. Warrell Gallium nitrate for the treatment of bone metastases Cancer 80 1997 1680 1685
23. M. Sekine, and H. Takami Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia Oncol Rep 5 1998 197 199
24. P. Greipp, C.D. Williams, and A. Lipton A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN-0007) causes a profound and sustained decrease of bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma Blood 98 2001 775a
25. T. Berghmans, M. Paesmans, and J.J. Body A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis Support Care Cancer 8 2000 192 197
26. G. Decaux Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide Am J Med 2001 110 2001 582 584
27. G. Decaux Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985 J Lab Clin Med 138 2001 18 21
28. G. Decaux, Y. Waterlot, F. Genette, and J. Mockel Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide N Engl J Med 304 1981 329 330
29. A. Altman Acute tumor lysis syndrome Semin Oncol 28 2001 3 8
30. S. Sallan Management of acute tumor lysis syndrome Semin Oncol 28 2001 9 12
31. R.V. Smalley, A. Guaspari, S. Haase-Statz, S.A. Anderson, D. Cederberg, and J.A. Hohneker Allopurinol: intravenous use for prevention and treatment of hyperuricemia J Clin Oncol 18 2000 1758 1763
32. J. Feusner, and M.S. Farber Role of intravenous allopurinol in the management of acute tumor lysis syndrome Semin Oncol 28 2001 13 18
33. S.C. Goldman, J.S. Holcenberg, and J.Z. Finklestein A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis Blood 97 2001 2998 3003
34. M. Leach, R.M. Parsons, J.T. Reilly, and D.A. Winfield Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy Clin Lab Haematol 20 1998 169 172
35. A.O. Hoff, and R. Vassilopoulou-Sellin The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia Cancer 82 1998 1585 1592
36. P.E. Cryer Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness Endocrinol Metab Clin North Am 28 1999 495-500
37. E.M. Sillos, J.L. Shenep, G.A. Burghen, C.H. Pui, F.G. Behm, and J.T. Sandlund Lactic acidosis: a metabolic complication of hematologic malignancies. Case report and review of the literature Cancer 2001 92 2001 2237 2246
38. K.K. Naing, J.A. Dewar, and G.P. Leese Megestrol acetate therapy and secondary adrenal suppression Cancer 86 1999 1044 1049
39. P. Kann, C. Hengstermann, C.P. Heussel, F. Bittinger, M. Engelbach, and J. Beyer Endosonography of the adrenal glands: normal size - pathological findings Exp Clin Endocrinol Diabetes 106 1998 123 129
40. A. Kawashima, C.M. Sandler, and E.K. Fishman Spectrum of CT findings in nonmalignant disease of the adrenal gland Radiographics 18 1998 393 412
41. J.G. Gonzalez-Gonzalez, N.E. De la Garza-Hernandez, L.G. Mancillas-Adame, J. Montes-Villarreal, and J.Z. Villarreal-Perez A high-sensitivity test in the assessment of adrenocortical insufficiency: 10 microg vs 250 microg cosyntropin dose assessment of adrenocortical insufficiency J Endocrinol 159 1998 275 280